EPISODE · Feb 12, 2026 · 12 MIN
Axi-Cel and 5-FU Label Changes
from OncoPharm · host John Bossaer
We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)
Embed this episode
Ready to play
Axi-Cel and 5-FU Label Changes
0:00
12:34
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of OncoPharm?
This episode is 12 minutes long.
When was this OncoPharm episode published?
This episode was published on February 12, 2026.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!